CD274 and neoplasm: Notably, when this analysis was restricted to the 46 patients with non-MSI-H (StrataNGS clinical testing) tumors in non-PD(L)1 monotherapy approved tumor types, only IRS-H patients still had significantly longer pembrolizumab monotherapy rwPFS than the immediately preceding line of therapy (IRS-H pembrolizumab vs. immediately preceding therapy median rwPFS 11.9 [95% CI: 7.8–NA] vs. 3.2 [95% CI: 2.3–9.6] months, log rank, p = 0.005; Fig. S16a, b).